The 3F8 anti-MBL-2 monoclonal antibody was administered to a murine model of atypical hemolytic uremic syndrome and was shown to attenuate C3d deposition and renal injury, suggesting that MBL2 inhibition is a mitigating factor in vivo (102). Here, MBL2 is linked to atypical hemolytic-uremic syndrome.